All three peroxisome proliferator-activated receptors (PPARA, PPARD, and PPARG) attenuate NAFLD and thus were suggested as therapeutic targets for the treatment of NAFLD [5–7]. The gene discussed is PPARD; the disease is metabolic dysfunction-associated steatotic liver disease.